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Abstract—Gene expression profiles have been widely used to
characterize patterns of cellular responses to diseases. As data
becomes available, scalable learning toolkits become essential to
processing large datasets using deep learning models to model
complex biological processes. We present an autoencoder to
capture nonlinear relationships recovered from gene expression
profiles. The autoencoder is a nonlinear dimension reduction
technique using an artificial neural network, which learns hidden
representations of unlabeled data. We train the autoencoder on
a large collection of tumor samples from the National Cancer
Institute Genomic Data Commons, and obtain a generalized and
unsupervised latent representation. We leverage a HPC-focused
deep learning toolkit, Livermore Big Artificial Neural Network
(LBANN) to efficiently parallelize the training algorithm, reduc-
ing computation times from several hours to a few minutes. With
the trained autoencoder, we generate latent representations of a
small dataset, containing pairs of normal and cancer cells of
various tumor types. A novel measure called autoencoder node
saliency (ANS) is introduced to identify the hidden nodes that best
differentiate various pairs of cells. We compare our findings of
the best classifying nodes with principal component analysis and
the visualization of t-distributed stochastic neighbor embedding.
We demonstrate that the autoencoder effectively extracts distinct
gene features for multiple learning tasks in the dataset.
I. BACKGROUND AND MOTIVATION
Cancer is a group of genetic diseases, characterized by the
development of abnormal cells that have the ability to infiltrate
and destroy normal body tissues [1]. Cancer genome sequenc-
ing has fundamentally improved our understanding of muta-
tions in cancer cells. The discoveries through cancer genome
sequencing show that mutational processes vary among tumors
and cancer types [2], [3]. Identifying the genomic alterations
that arise in cancer can help doctors select treatments based on
their distinct molecular abnormalities. Interesting findings in
gene expression profiles provide implications of how normal
cells evolve into cancer cells. Zhang et al. [4] analyzed gene
expression patterns in gastrointestinal tumors, and Welsh et al.
[5] identifies candidate molecular markers of epithelial ovar-
ian cancer. Most studies employ direct comparisons between
normal and cancer cells using statistical measurements.
Large-scale gene expression profiles can consist of thou-
sands of features. To reduce the cost of profiling and satisfy a
reasonable number of features for limited sample sizes [6]–[8],
This work has been supported in part by the Joint Design of Advanced
Computing Solutions for Cancer (JDACS4C) program established by the U.S.
Department of Energy (DOE) and the National Cancer Institute (NCI) of the
National Institutes of Health.
a subset of genes are frequently pre-selected based on high
variability [9], [10]. However, advances in sequencing now
allow for more profiling of a larger set of genes in non-clinical
diagnostic settings. Research has shown that deep learning
is able to handle a larger number of features and perform
better than the linear methods used for selecting landmark
genes [11]. It implies that deep learning could capture complex
nonlinear relationships between expressions of genes missed
by linear methods. Although kernel machines can represent
useful nonlinear patterns [12], they do not scale well to the
growing data size of expression profiles. Thus, deep learning
enjoying both representability and scalability is ideal for large-
scale non-linear gene expression feature extraction [11].
A massive proportion of cell lines used in biomedical
research is mislabeled [13], [14], causing potentially erroneous
findings. Supervised learning uses class labels, i.e. the re-
sponses of the observations, to guide the training algorithm
and can be successful in data classification. However, its
performance is sensitive to the quality of the labels.
Motivated by these results, we demonstrate the potential of
applying deep learning methods on large-scale gene expression
profiles. We focus on the unsupervised learning method, called
the autoencoder, which is an artificial neural network that
transforms data into a meaningful latent space. Since no tumor
type labels are considered when training the autoencoder,
the algorithm avoids being misled by false labeling. It has
been applied on genome-wide assays of cancer for knowledge
extraction using their unsupervised nature. The denoising
autoencoders generate latent representations to classify breast
cancer cells from normal control cells [15], [16]. Variational
autoencoders are built on the genomic data [17] where ex-
planatory features are obtained by subtracting a series of
mean values of latent representations to obtain insights linking
specific features to biological pathways. These models are built
on selected gene sets, ranging from 2,520 to 15,000 genes.
Existing autoencoder methods do not give a rigorous metric
for rank ordering hidden network nodes to explore and operate
on small training sets.
The novelty of this work is in the following. First, we
apply transfer learning [18] to overcome the problems of
high dimension, low sample size data [8], [19]. We train
the autoencoder on a large collection of tumor samples to
obtain a generalized latent representation. We include all
60,483 measured transcripts, which requires a large amount
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of computing resources. With its optimal parameters, we
compute latent representations of a small dataset containing
pairs of normal and cancer cells. Second, we use the latent
space to characterize complex gene expression activations
existing in different tumor types. This is done by applying
the autoencoder node saliency (ANS) [20] to rank the hidden
projections according to their ability to classify normal and
cancer cells of different tissue types. Furthermore, we leverage
a HPC-focused deep learning toolkit, Livermore Big Artificial
Neural Network (LBANN) to efficiently parallelize the train-
ing algorithm, reducing computation times from several hours
to a few minutes.
II. DATA DESCRIPTION
The National Cancer Institute Genomic Data Commons
(GDC) data portal provides unified genomic data from patients
with cancer [21]. We obtained two datasets for our analysis,
a collection of pairs of normal and cancer cells and a large
collection of GDC tumor samples. Both datasets contain cell
lines measured by the same 60,483 transcripts. The first dataset
contains pairs of normal and cancer cells from 23 cancer types.
Since some cancer types have very small number of samples,
we select tumor types that have larger than 40 pairs of normal
and cancer cells, making a total of 533 cell pairs across nine
cancer types for our experiments. Careful attention was given
to exclude samples in the test dataset from samples in the
training dataset, and in particular, all cancer-normal pairs were
excluded from training. A detailed description of these tumor
types and their numbers of samples are shown in Table I.
Since the first dataset has a relatively larger number of
features (60,483) to the number of samples (1,066), we need a
sufficient number of training samples in order to obtain a good
performing neural network [7]. Therefore, the second dataset
is designated for training the autoencoder for obtaining a more
generalized latent representation. It consists of 11,574 tumors
from 28 cancer types.
In Figure 1, we visualize the distribution of the normal
and cancer cell pairs using t-distributed stochastic neighbor
embedding (t-SNE). The t-SNE [22] is a nonlinear dimension
reduction technique that projects the high-dimensional data
in two-dimensional space. It locates similar high-dimensional
data points next to each other in the low dimension, at the
same time puts dissimilar high-dimensional data points away
from each other. It largely avoids overlapping data points
for visualization. Although the euclidean distance is used as
the base of its similarity metric in the original space, the
distances are not preserved. Therefore, the projection in the
lower dimension is only for understanding the similarity and
dissimilarity of the data clusters.
Since tumor types are not considered when generating
the t-SNE plot, in Figure 1, we see that each tumor type
naturally forms a cluster, and within the same tumor types the
normal cells are gathered in a cluster and the cancer cells are
gathered in another. Each pair of the normal and cancer cells
is connected with an arrow. The arrows identify data points far
away from their tumor type clusters where data points could
have been mislabeled. For example, there is a small cluster
between the breast cluster and the lung cluster, which contains
mixed cancer cells that are difficult to classify.
TABLE I
DESCRIPTION OF THE CANCER AND NORMAL CELL PAIRS AND THEIR
CORRESPONDING NUMBER OF SAMPLES. WE CONSIDER THE TUMOR
TYPES THAT HAVE MORE THAN 40 SAMPLES.
Cancer Cell Normal Cell Count
Breast Invasive Carcinoma Breast 112
Prostate Adenocarcinoma Prostate 51
Lung Squamous Cell Carcinoma Lung 49
Lung Adenocarcinoma Lung 57
Thyroid Carcinoma Thyroid 58
Kidney Renal Clear Cell Carcinoma Kidney 72
Colon Adenocarcinoma Colorectal 41
Head and Neck Squamous Cell Carcinoma Head and Neck 43
Liver Hepatocellular Carcinoma Liver 50
III. AUTOENCODER NODE SALIENCY
A. Notation
In this paper, matrices are denoted by bold uppercase letters,
vectors by bold lowercase letters and scalars by letters not in
bold. Let A be a matrix whose i-th row vector is ai, and b be
a vector whose s-th element is bs. The element at the i-th row
and the j-th column of A is ai,j . Let 1 be a vector of all ones
with a suitable dimension. The cardinality of a set T is |T |. We
denote a dataset as X ∈ [0, 1]n×d that contains n data points
xi ∈ [0, 1]d of d-dimensional variables for i = 1, . . . , n.
B. Autoencoder
Autoencoder builds a lower-dimensional representation of
the data through a pair of maps X
f→ A g→ X . The first
map is the encoder A = f(X) and the second is the decoder
X′ = g(A). Using m hidden nodes in the neural network, the
encoder performs dimension reduction on the input X and
transforms the data of dimension d to a reduced dimension
m where m < d; the decoder performs a reconstruction,
mapping the data from the reduced dimension m back to the
original dimension d. This is done so that the reconstruction
error between X and g(f(X)) is small. Usually autoencoders
are restricted so that they do not simply learn the input set
perfectly, but prioritize which aspects of the input should be
kept. Hence, autoencoders often learn useful properties of the
data [23].
The latent representation of the dataset X is defined as
A = f(X) = σ(WXT + b), (1)
where W ∈ Rm×d and b ∈ Rm are weight vector and bias
in the linear transform; and σ is the activation function in
the nonlinear transform. Most activation functions in neural
networks try to capture the rate of action potential, whose
simplest form is a binary function. We use the sigmoid
function, σ(z) = (1 + e−z)−1, to handle such design where
the action frequency increases quickly at first, but gradually
approaches an asymptote at 100 percent action.
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Fig. 1. Visualization of the normal and cancer cell pairs using two dimensional tSNE.
The decoder then maps the activation A to the reconstruc-
tion X′ to the same dimensional space of X ,
X′ = g(A) = σ(W TA+ b′)T,
where b′ ∈ Rd is the bias term in the decoder. We train the
autoencoder on the GDC dataset by finding optimal solutions
for W ∗, b∗ and b′∗ that minimize the mean squared error, the
difference between X and X′.
After training an autoencoder on the GDC dataset X , we
are interested in identifying features in the autoencoder that
can be used to distinguish between normal and cancer cells .
Given a hidden node s (for s = 1, . . . ,m), we transform the
normal and cancer cell pairs Xˆ in the GDC features to their
latent representations (also called activation values):
as = σ(w
∗
sXˆ
T + b∗s · 1). (2)
Autoencoder node saliency (ANS) [20] is based on the
histograms of the activation values. The vector as at node
s can be described using a one-dimensional histogram. The
activation values are in the range of (0, 1), due to our selection
on the activation function, the sigmoid, that restricts the range
of projection. A histogram contains a set of k bin ranges,
B = {[0, 1k ), [ 1k , 2k ), . . . , [k−1k , 1]}, where [a, b) indicates val-
ues ≥ a and < b. Simply, the r-th bin range in the set
B is Br = [ r−1k ,
r
k ) for r = 1, . . . , k. The ANS method
contains two parts. The first part is the unsupervised node
saliency that measures the “interestingness” of the histograms,
using normalized entropy difference (NED). The second part
is the supervised node saliency (SNS) that incorporates the
distribution of the two class labels in the histograms.
C. Unsupervised node saliency
Given the constructed histogram, we first compute the
entropy of the latent representations at the hidden node s for
s = 1, . . . ,m, defined by:
E(as) = −
∑
r
p(Br,as) log2 p(Br,as);
where |as| = nˆ, the number of data points encoded, and
p(Br,as) ≡ |{i | as,i ∈ Br}||as| , (3)
is the probability of the activation values as occurring in the
r-th bin range of the histogram for r = 1, . . . , k. To compare
different histograms, the unsupervised node saliency utilizes
the normalized entropy difference (NED) defined as
NED(as) =
log2 kˆ − E(as)
log2 kˆ
= 1 +
1
log2 kˆ
∑
r
p(Br,as) log2 p(Br,as),
(4)
where kˆ is the number of occupied bins. Note that log2 kˆ is
the maximum entropy of as (E(as)) when p(Br,as) = 1/kˆ
for all occupied bins.
After training the autoencoder without considering class
labels, we examine whether the features constructed by the
autoencoder exhibit properties related to known class labels,
which are the normal cells labeled as 0 and the cancer cells
labeled as 1. We define pc(Br,as) as the probability that the
activation values from one of the two classes, c ∈ {0, 1} occur
in the bin range Br, which is
pc(Br,as) ≡ |{i | as,i ∈ Br and yi = c}|
nc
,
where nc is the number of data points in class c. Using (4)
for each of the classes, we obtain the supervised NED defined
as:
NEDc(as) = 1 +
1
log2 kˆ
∑
r
pc(Br,as) log2 pc(Br,as). (5)
The autoencoder node saliency evaluates three values: NED
defined in (4) on the data of the two classes, 0 and 1,
combined; as well as NED0 and NED1 defined in (5), each
on the data from one of the two classes.
Note that the range of NED is between zero and one. When
NED equals one, the node’s activation value is near constant,
occupies only one bin and low information content. A high
value of NED (below 1) indicates that most of the activation
values are settled in a few bins giving an “interesting” profile.
A low value of NED corresponds with activation values spread
evenly over all the bins, indicating “uninteresting” nodes.
Node saliency increases with NED, except for the extreme
case when NED equals one. Therefore, a good classifying node
has activation values from one class take up a few bins in the
histogram, with a different set of bins occupied by the other
class. Since the activation values from both classes occupy
the union of these bins, the data distribution combining both
classes is less “interesting” than the data distribution of each
individual class. A good classifying node has a property that
satisfies both NED < NED0 and NED < NED1 [20].
D. Supervised node saliency
The NED values reveal the “interestingness” of the latent
representations at each of the autoencoder hidden nodes. To
rank the hidden nodes according to their capability of separat-
ing the normal and cancer cells, we apply the supervised node
saliency (SNS) [20] that measures the binomial proportions
of the two classes in the histogram. The SNS compares a
distribution q against a fixed reference distribution p. It is at
its minimal value when q = p. The distribution q varies at
different hidden nodes. It is constructed using the binomial
proportions at each bin range r of activation values at node s
defined in (6).
qr = prob{yi = 1 | as,i ∈ Br}
≡ |{i | as,i ∈ Br and yi = 1}||{i | as,i ∈ Br}| .
(6)
The fixed reference distribution p is designed manually using
binary distribution defined in (7), where one class totally
occupies half of the bins at one end, and the other class falls
on the other half of the bins.
pr =
{
0 if r < k/2
1 if r ≥ k/2. (7)
The SNS applies weighted cross entropy (WCE) employing
a weight, p(Br,as), at each bin r. For notation convenience,
we let p(Br) = p(Br,as). The SNS is defined as
SNS ≡ min
{
WCE0,WCE1
}
,where (8)
WCE1 =
∑
r
p(Br)
[
− pr log2 qr − (1− pr) log2(1− qr)
]
and
WCE0 =
∑
r
p(Br)
[
− (1− pr) log2 qr − pr log2(1− qr)
]
.
The SNS gives one value for each of the hidden nodes
measuring the similarity of their binomial distributions on the
two classes to the binary distribution p. A smaller value of
SNS at a hidden node indicates that its class distribution is
closer to p, where the two classes are perfectly separated.
Thus, we rank the hidden nodes in the ascending order of
SNS.
The autoencoder node saliency identifies best classifying
hidden nodes and contains two steps. The first is to order the
hidden nodes according to the SNS, and the next is to interpret
the latent representations based on their NED values.
IV. PARALLELIZATION WITH LBANN
A. LBANN overview
The deep learning algorithm described in Section III-B was
implemented using the Livermore Big Artificial Neural Net-
work (LBANN) toolkit. LBANN is an open source framework
being developed at US DOE Lawrence Livermore National
Laboratory for training deep neural networks at scale (that is,
on very large data sets and with large models) with a specific
focus on HPC environments [24]. As an HPC-centric toolkit,
LBANN is optimized for both strong and weak scaling and
it is designed to exploit multiple parallelism schemes: intra-
and inter-model data parallelism (distributing data samples
across processes) and model parallelism (distributing model
parameters across processes).
At the core of LBANN is the Elemental math library [25].
Elemental is MPI-based and it provides highly optimized
data structures and algorithms for distributed linear algebra.
It handles most of the distributed data management and its
distributed matrix multiplication routine does the heavy lifting
for model parallel computation. When GPUs are available,
LBANN uses custom CUDA kernels and optimized cuDNN
routines to perform much of the computation. LBANN’s
data readers have support for data staging through node-local
NVRAM and can ingest data in various forms.
B. Scaling results
Scaling experiments were run on the Surface and Catalyst
clusters at Lawrence Livermore National Laboratory [26].
Surface consists of 156 compute nodes, each with a 16-core
Intel Sandy Bridge CPU, 256 GB memory, and two Tesla
K40 GPUs. Catalyst consists of 324 nodes, each with two
12-core Intel Xeon E5-2695 v2 CPUs, 120 GB RAM, 800
GB NVRAM, and dual InfiniBand QDR network interfaces.
Strong scaling experiments were conducted on both Surface
and Catalyst HPC clusters by varying the number of compute
nodes with the problem size fixed. Figure 2 shows strong
scaling results of training the autoencoder model on up to
8 and 128 computer nodes for Surface and Catalyst cluster
respectively. We observed reductions in the running time as
the number of compute nodes increased. The modest strong
scaling reduces the overall computation time to convergence
of the autoencoder model from several hours to a few minutes.
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Fig. 2. Strong scaling results on Catalyst (CPU cluster) and Surface (GPU
cluster)
V. EXPERIMENTAL RESULTS
A. Training the autoencoder
To determine the appropriate parameter settings for the
GDC dataset, we perform a full factorial design over all
combinations of selected parameter values. Details of the
training method can be found in Chapter eight of the deep
learning book [23]. We started at a wide range of random
parameter selections and then narrowed down to those that
give better performance. The parameters are: hidden layer size
of 500 and 1000; batch size of 25, 50, 100 150 and 200; and
learning rate of 0.00001, 0.00005, 0.0001, 0.00025, 0.0005,
0.00075 and 0.001. The best epoch sizes are chosen when the
cost function stops decreasing and the Pearson correlation of
the reconstruction stops increasing. We split the dataset into
a training set and a validation set. We use the validation set
to evaluate the model during the training process and limit
overfitting the model. The best parameter combination was
batch size 200 and learning rate 0.00005 at 230 epochs with
1000 hidden nodes. This setting gives a Pearson correlation of
0.8574 on the validation set.
B. Principal components analysis
The autoencoder is a nonlinear generalization of principal
components analysis (PCA) [27]. PCA finds the directions
of largest variances in the dataset and projects each data
point on each of these directions through linear transform.
In an autoencoder if a linear transfer function is used as an
activation function, a single layer autoencoder is similar to
PCA. Using the same training scheme as the autoencoder,
we first applied PCA on the GDC tumor collection. Then
the top two eigenvectors of the PCA are used to project
the normal and cancer cell pairs on the first two principal
components shown in Figure 3. We can see that clusters of
normal and cancer cells of different tumor types are formed
and overlapped on the first two principal components. A
close look on the second principal component shows well
separated normal cells from their paired cancer cells of three
tumor types: kidney, colorectal and head & neck. The linear
projection of PCA using the directions of the largest variance
(i.e. the first principal component) does not necessarily lead
to distinguishing clusters of desired tumor types. PCA is often
combined with other machine learning methods to demonstrate
its strength of dimension reduction [28] [29].
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Fig. 3. The normal and cancer cell pairs projected on the first two principal
components. The PCA was trained on the GDC cancer cell collection.
C. Identifying best classifying nodes
After training the autoencoder, we acquire optimal weight
W ∗ and bias b∗ for the GDC tumor collection. We can then
generate latent representations for any sample points in the
collection of pairs of normal and cancer cells. There are 1000
hidden nodes in the autoencoder. For each hidden node s for
s = 1, . . . , 1000, we transform the cell data of GDC features
to their latent representations using the activation function (2).
Each best node s corresponds to the weight vector w∗s that
connects the input and the hidden layer, and determines how
each gene in the input layer influenced the activation values of
the node. Therefore, we are interested in identifying the hidden
nodes that best classify normal and cancer cells for different
tumor types. We first apply supervised node saliency (SNS) to
the latent representations of the data subset intended for each
learning task. For example, to differentiate the breast cancer
cells from the normal cells, we collect the 112 pairs of tumor
samples of the breast normal and breast cancer and construct
their latent representations A. That is A = [as]s=1,...,m.
Then using (8), (4) and (5), respectively, we compute the
autoencoder node saliency values: SNS that orders the hidden
nodes; NED, NED0 and NED1 that interpret the classification
distribution.
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Fig. 4. Top 500 hidden nodes ranked by the supervised node saliency (SNS)
on the breast dataset. The original node numbers appear every 20 nodes. The
best node for classifying the normal and cancer cells of breast is Node 316.
Figure 4 displays the top 500 (out of 1000) hidden nodes
ranked in increasing order of their SNS values on the normal
and cancer cells of breast. The SNS curves for most binary
classification tasks in the dataset are similar to the curve in
the figure. Only the top few nodes have low SNS values close
to zero, while the majority of the rest nodes are close to 0.8.
The best node for classifying the normal and cancer cells of
breast is node 316. The histogram of node 316 that describes
the distribution of the normal and cancer cells of breast is
shown in the first histogram in Figure 6. We observe that the
normal and cancer cells of breast are very well separated in
node 316 with a small percentage of cancer cells allocated at
the cluster of the normal cells. This result is consistent with
the cell clusters shown in the t-SNE plot (Figure 1). The t-
SNE indicates that there exist a small cluster of mixed cancer
cells next to the normal breast cells. There are also a few breast
cancer cells that are similar to normal cells. These cancer cells
are difficult to differentiate.
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< NED0 and NED < NED1, the property of good classifying nodes.
The next step of the autoencoder node saliency is to verify
the property of a good classifying node on the top SNS nodes.
As discussed in Section III-C, a good classifying node meets
both conditions: NED < NED0 and NED < NED1. Figure 5
displays the NED values of the top 100 hidden nodes ranked
by the SNS values for the breast cell pairs. The top six nodes,
including node 316, satisfy the property of a good classifying
node, while the rest of the nodes do not.
The SNS values allow us to compare different classification
tasks. Since SNS is computed by comparing the activation
distribution to a fixed reference distribution (7), histograms
with a better classification have lower SNS values. Histograms
of the best classifying nodes that separate cancer from normal
are shown in Figure 6, each for one of the nine tumor types
(in Table I). The histogram of the best classifying node (node
581) for all tumor types combined is shown in the last figure.
Their corresponding SNS values are also listed on the top of
the histogram. Distinguishing between kidney renal clear cell
carcinoma and normal kidney (node 773) is the easiest task
among the ten tasks, with the lowest SNS at 0.0101. Only a
small number of normal kidney cells mixed with the cluster
of the kidney renal clear cell carcinoma. Among individual
tumor types, prostate adenocarcinoma is the most difficult to
separate from prostate normal cells. The best classifying node
for prostate is node 450 with SNS at 0.2685. This is again
consistent with the t-SNE plot (Figure 1) where there is barely
a space between the cluster of prostate adenocarcinoma and
the cluster of prostate normal. The most difficult classification
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Fig. 6. Best classifying nodes of the trained autoencoder for distinguishing
between normal and cancer cells in each tumor type.
is to separate cancer from normal considering all tumor types
at the same time. Node 581 has the largest SNS at 0.4482 and
a large number of mixed cancer and normal cells.
Research indicates that mutational processes vary among
tumors and cancer types [2], [3]. Tumor types play a significant
role in understanding how certain genes are altered by muta-
tions [3]. To further demonstrate the value of the autoencoder
node saliency method, we randomly select six pairs of tumor
types (including both the tumors and normal cells) and display
their distribution on their best classifying nodes in Figure 7.
Node 198 with SNS at 0.0319 is the best classifying node for
separating lung squamous cell carcinoma and breast invasive
carcinoma, considering both tumor and normal tissue. The
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Fig. 7. Best classifying nodes of the trained autoencoder for distinguishing
between tumor types together with their corresponding normal cells. We
display six random pairs of the tumor types.
smallest SNS among these tumor type pairs is node 754 and
752, having SNS at its minimum, with the least misclassified
cells in the latent representation of the hidden node. The node
754 is the best classifying node for differentiating kidney from
both thyroid and colorectal tumors; while the node 752 is the
best classifying node for separating liver from head & neck.
These tumor types are far away from each other in their t-SNE
plot.
The normal lung cells could turn into lung squamous cell
carcinoma or lung adenocarcinoma. Since their normal cells
are from the same category, we only consider the latent
representations from the two lung cancer types for computing
SNS. The histogram of the best node is shown in Figure 8. We
find that node 195 best classifies the two lung cancers with
SNS at 0.0995.
Recall that PCA is able to separate cancer from normal
for three cancer types (Figure 3) at the second principal
components. The eigenvalues of PCA indicates the data vari-
ances along the principal components. However, whether other
principal components contain clusters of different tumor types
is still to be inspected. The autoencoder presents a useful alter-
native to PCA, which captures the t-SNE similarity. Moreover,
through the use of the autoencoder node saliency method we
can efficiently extract interesting features that could describe
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Fig. 8. The best classifying node that separates the two lung cancers, Lung
Squamous Cell Carcinoma and Lung Adenocarcinoma. Their corresponding
normal cells are ignored.
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Fig. 9. The distributions of weights for all 60,483 transcripts to the best
classifying nodes. Each node separates cancer cells from normal cells of a
different tumor type. We randomly select five tumor types for the plot.
the visualized patterns.
The identified autoencoder nodes not only reflect the high
similarity of the tumor types in the t-SNE plot, but also point
out distinctive genes without using any class labels, which t-
SNE is not able to reveal. The distribution of weights for all
60,483 transcripts to a single node approximately resembled
a bi-model distribution with one mode centered around zero
and a second centered around -0.225 as shown in Figure 9.
We randomly select five tumor types for display. The majority
of the transcripts have zero or low weights in a hidden node;
while a small portion of the genes have high negative weights.
Each node has a unique distribution of weights. We can
withdraw common genes among different tumor types and
extract speciality genes from individual tumor types for further
analysis. The weights of the best classifying nodes provide
links from the latent representations back to the original genes
that stimulate the evolution of normal cells into cancer cells.
VI. CONCLUSION
An autoencoder model is trained on a large collection of
tumor samples (11,574) represented by 60,483 measured tran-
scripts from the GDC data portal. It provides a generalized and
unsupervised latent representation of cancer cells. We lever-
age the scalable learning toolkit, LBANN, to take advantage
of available HPC systems, thus reducing computation time.
Experimental results from LBANN show strong scaling on
CPU and GPU clusters. This scalability provides opportunities
for quick massive hyperparameter exploration. There are 1000
hidden nodes in the autoencoder. After training the autoen-
coder, each hidden node has a corresponding optimal weight
and a bias. We use them to compute the latent representations
of a small but non-overlapping dataset, containing 533 pairs
of normal and cancer cells of multiple tumor types.
Autoencoder node saliency (ANS) determines the best
classifying node using two measurements: SNS to rank the
hidden nodes and NED to verify classifying properties. The
results show that the autoencoder constructed from the large
collection of tumor samples is able to identify features in the
small dataset of the paired normal and cancer cells. The pairs
of the normal and cancer cells of the nine various cancer
types are visualized using t-SNE, which reveals the similarity
and dissimilarity of these data points. However, the actual
distances in t-SNE are not preserved. We demonstrate that
the identified best classifying nodes of the autoencoder are
able to fill the missing connection between the visualized data
clusters and their underlying distinctive factors. ANS found
the best classifying nodes that distinguish between normal and
cancer cells for each of the tumor types. It also revealed the
hidden nodes that separate different tumor types. Moreover,
the weights of the best classifying nodes provide links from
the latent representations back to the original genes. We are
able to extract the speciality genes that stimulate the evolution
of normal cells into cancer cells.
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